#Covaxin Lancet study
Text
Covaxin safe, immunogenic in children aged 2-18 years: Lancet | India News
Covaxin safe, immunogenic in children aged 2-18 years: Lancet | India News
HYDERABAD: Bharat Biotech International Limited (BBIL)’s whole-virion inactivated Covid-19 vaccine candidate Covaxin has proven to be safe, well-tolerated, and highly immunogenic in children aged 2-18 years in a phase II/III study, the results of which have been published in the prestigious, peer-reviewed Lancet Infectious diseases, peer reviewed high impact factor journal. Bharat Biotech said…
View On WordPress
0 notes
Text
COVAXIN Latest Peer Review Shows Robust Safety, Immunogenicity in 2-18 Years Old
#COVAXIN Update @bharatbiotech Universal vaccine COVAXIN Latest Peer Review in @TheLancetI has proven it to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study in 2-18 Years Old. #CovidVaccines #Covid19 #PeerReview
Bharat Biotech today announced COVAXIN Latest Peer Review published in the Lancet Infectious Disease Journal . The company stated, the peer review of BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study.
The study has been accepted and published in Lancet Infectious…
View On WordPress
0 notes
Text
Covaxin shows 50% effectiveness against symptomatic COVID in real-world assessment: Lancet study
Covaxin shows 50% effectiveness against symptomatic COVID in real-world assessment: Lancet study
Image Source : PTI/ REPRESENTATIONAL (FILE).
Covaxin shows 50 per cent effectiveness against symptomatic COVID in real-world assessment: Lancet study.
Highlights
Results of study published in The Lancet showed that 2 doses of Covaxin had 77.8 pc efficacy
Researchers noted that Delta variant was dominant strain in India during study period
Covaxin was approved for emergency use in India for…
View On WordPress
#covaxin#Covaxin effectiveness#Covaxin Lancet study#Covaxin latest news updates#Covaxin news#Covaxin real world assessment#Covaxin symptomatic#COVID#Delta variant#latest coronavirus pandemic news updates
0 notes
Text
What is a ‘precaution dose’ and how is it different from a ‘booster dose’?
Top government sources told The Indian Express that there is preliminary consensus in the country’s top technical advisory body on Covid vaccination that the third dose of Covid-19 vaccines must be different from the primary unit used for the first two doses.
It is very likely that the precautionary dose will be a vaccine of a different platform, government sources were quoted as saying.
‘So, the preliminary consensus is,’ a source continued, ‘that a beneficiary cannot take three doses of Covishield or Covaxin.’
What are alternatives for third doses then?
According to top virologist, Dr. Gagandeep Kang, the best booster shots available are that of mRNA vaccines.
She also added that while India could get Pfizer or Moderna vaccines which are mRNA based or wait for the indigenous mRNA vaccine being developed by Pune-based Gennova Biopharmaceuticals Ltd.
Also Watch: Omicron: Potential scenario that our vaccines may become ineffective, says Covid panel chief
Other likely alternatives can be vaccines being manufactured by Indian pharmaceuticals, Hyderabad based Biological E’s Corbevax, Serum Institute of India’s Covovax and Bharat Biotech’s intranasal vaccines.
These vaccines are expected to be rolled out in 2022 for the general population.
While booster shots are being recommended by experts across the world, pharma company Cipla’s CEO Umang Vohra is of the opinion that third doses will not be as beneficial in the long run.
‘Covid-19 will soon become a common flu so what happens with the flu vaccines is that every year booster doses are created around a particular strain of the flu that was seen last,’ Vohra explained.
Read More: What is a ‘precaution dose’ and how is it different from a ‘booster dose’?
Source: editorji.com
Also Watch: Mixing vaccines with AstraZeneca, Pfizer induces strong immune response: Lancet study
Watch all the Latest Video News, Lifestyle Video News and Health News on editorji.com
0 notes
Text
Bharat Biotech update the efficacy of Covaxin to 65.2% against the Delta variant, Health News, ET HealthWorld
Bharat Biotech update the efficacy of Covaxin to 65.2% against the Delta variant, Health News, ET HealthWorld
Commending the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases, Bharat Biotech stated that these results provide evidence for effectiveness for COVAXIN in real life settings. Updated the efficacy of Covaxin to 65.2 percnt against the Delta variant in – Effectiveness Study on Delta Variant – Lancet Infectious Diseases, published on Tuesday.
“An effectiveness…
View On WordPress
0 notes
Photo
Covaxin 50% effective against Delta variant, shows Lancet study.
More here: https://hydnews24.com/recent-news/covaxin-50-effective-against-delta-variant-shows-lancet-study/
0 notes
Text
India : Efficacy of Covaxin is only 50% against symptomatic covid19
India : Efficacy of Covaxin is only 50% against symptomatic covid19
India : Efficacy of Covaxin is only 50% against symptomatic covid19
Two doses of Covaxin are 50% effective against symptomatic Covid19, according to the first real-world assessment of India’s indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal.
Researchers also noted that the Delta variant was the dominant strain in India during the period of the study. At that…
View On WordPress
#Bharat Biotech&039;s Covaxin#covaxin#covaxin news#covid19 india latest news#india#India : Efficacy of Covaxin is only 50% against symptomatic covid19#india covid19#india covid19 latest news#india covid19 vaccine#india latest news#india news#India news today#indian news
0 notes
Text
First real-world study: Covaxin effectiveness 50%
First real-world study: Covaxin effectiveness 50%
Two doses of Covaxin have 50 percent effectiveness against symptomatic COVID-19, suggests the first real-world evaluation of the effectiveness of a vaccine developed in India.
The study, published in the journal The Lancet Infectious Diseases, assessed 2,714 hospital workers at AIIMS, New Delhi who were symptomatic and underwent RT-PCR test for coronavirus between April 15 and May 15 this year.…
View On WordPress
#coronavirus vaccine#Covaxin#Covaxin efficacy#coveshield efficacy#Covid Vaccination#covid vaccine#Cowishield#current#harpianews#India#India COVID vaccine#Indian Express#latest#news
0 notes
Text
Top headlines: Lancet reviews Covaxin, China's Xi Jinping extends power
Top headlines: Lancet reviews Covaxin, China’s Xi Jinping extends power
Tata Steel has reported a consolidated net profit of Rs 11,918 crore in the September quarter, up nearly eight-fold from the same period last year. More in that story in our morning wrap.
Covaxin 77.8% effective against Covid in Lancet study
Covaxin, a vaccine developed by India’s government medical research agency and Bharat Biotech International Ltd., was found to have a 77.8 per cent…
View On WordPress
0 notes
Text
Covaxin demonstrates robust safety, immunogenicity in 2-18-year-olds: Bharat Biotech
Covaxin demonstrates robust safety, immunogenicity in 2-18-year-olds: Bharat Biotech
Bharat Biotech International Limited (BBIL) has announced on Friday that BBV152 (Covaxin), its whole-virion inactivated Covid-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in pediatric subjects in phase II/III study .
The study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal. Bharat Biotech had conducted…
View On WordPress
0 notes
Text
6 Key Findings of COVAXIN The Lancet Peer-Review
6 Key Study Findings Of COVAXIN @TheLancet The Lancet Peer-Review @bharatbiotech #Covaxin #Covid19 #Covid19Vaccines #MadeinIndia #TheLancet
COVAXIN The Lancet Peer-Review is out now which re-affirms its efficacy and safety. Bharat Biotech, a global leader in vaccine development and innovation, announced ( on Friday today morning) that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN® is peer reviewed and published in The Lancet. This study follows 10 other peer-reviews published in leading scientific…
View On WordPress
1 note
·
View note
Text
Covaxin safe, shows 77.8% efficacy against symptomatic COVID-19: Lancet study
Two doses of Covaxin, India’s indigenous COVID-19 vaccine, offer 77.8% protection against symptomatic disease and present no serious safety concerns, according to an interim analysis of its phase 3 trial published in The Lancet on Friday.
Covaxin, an inactivated whole virus vaccine developed by Hyderabad-based Bharat Biotech, recently received emergency use approval from the World Health Organization (WHO) for people aged 18 and above.
The phase 3 trial findings indicate that Covaxin induces a robust antibody response with no severe vaccine-related adverse events or deaths reported among the trial participants, the authors of the study said.
The majority of the adverse events, including headache, fatigue, fever, and pain at the injection site, were mild and occurred within seven days of vaccination, they explained.
The vaccine is administered in a two-dose regimen, 28 days apart, and can be stored and transported between 2-8 degrees Celsius.
The trial took place from November 16 to May 17 this year, with participants aged 18 and older randomly assigned to receive two doses of the vaccine or a placebo.
The researchers “recorded 24 positive cases among 8,471 people in the vaccine group and 106 positive cases among 8,502 people in the placebo group, suggesting an overall vaccine efficacy of 77.8 per cent”, the authors said.
They also noted that the data is preliminary and more research with larger sample size is needed to determine efficacy against severe disease and hospitalisation.
Participants considered to be at risk of acquiring COVID-19 were prioritised with 2,750 participants above 60 years of age and 5,724 participants who reported at least one pre-existing medical condition, such as cardiovascular disease, diabetes, or obesity, across ages.
This study was conducted with participants from diverse geographic locations across 25 hospitals in India.
The researchers conducted an efficacy analysis based on 130 laboratory-confirmed RT-PCR positive symptomatic COVID-19 among 16,973 initially seronegative participants.
These cases were recorded at least two weeks after participants had received a second dose.
The trial also found that Covaxin was well-tolerated among all trial participants, with 12 % of vaccine and placebo groups reporting an adverse event.
"The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals,” said Bharat Biotech Chairman Krishna Ella.
"The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world,” Mr. Ella said in a statement.
The study authors from Bharat Biotech and National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, noted that there was no clinically or statistically significant difference in serious adverse events between groups, and no cases of vaccine-related deaths.
"I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. This itself speaks high about the strong position of Covaxin amongst other global front-runners COVID-19 vaccines," said Indian Council of Medical Research Director General Balram Bhargava.
Analysis of immune responses induced by the vaccine showed that Covaxin produced a strong neutralising antibody response measured by the concentration of these antibodies at day 56 or one month after receiving the second dose.
A neutralising antibody defends a cell from an infectious particle by preventing any effect it has biologically.
Similar to the phase 1/2 studies, Covaxin-induced antibodies showed no significant decrease in neutralisation activity against the Alpha variant but demonstrated marginal reductions against other variants of concern, including Delta and Gamma.
Researchers conducted a preliminary analysis of efficacy against the Delta variant and found Covaxin to be 65 per cent effective against symptomatic COVID-19 infection from the variant.
They, however, cautioned that this data is preliminary and further observations are necessary to confirm clinical efficacy against Delta and other variants.
The study found no significant differences in immune responses across the broad age groups of under- and over-60-year-olds. The oldest trial participant was 97 years old.
The authors of the study also noted several limitations of the analysis.
Due to the low number of cases reported between the first and second vaccine doses, the researchers could not calculate vaccine efficacy after a single dose.
They said the analysis included safety follow-up of an average 146 days from the first dose for all participants, adding that long-term safety follow-up of Covaxin is required and is currently underway.
The study population was limited to India and therefore lacked ethnic and racial diversity, underscoring the importance of evaluating the efficacy of Covaxin in other populations.
“The roll-out of Covaxin might ease the ultra-cold chain requirements of other SARS-CoV-2 vaccine platforms, increase the finite global manufacturing capacity, and improve insufficient supply of vaccines which disproportionately affects low-income and middle-income countries,” said Jing-Xin Li and Feng-Cai Zhu of the Jiangsu Provincial Center for Disease Control and Prevention, China, who were not involved in the study.
“The next step for studies of Covaxin should be a focus on monitoring for epidemiological variations in SARS-CoV-2 and the long-term vaccine efficacy against symptomatic COVID-19 and asymptomatic infection to identify whether the vaccine provides ongoing protection when any variant of concern has occurred,” Mr. Zhu said in a statement.
Source
0 notes
Photo
Covaxin efficacy stands at 77.8%, says peer-reviewed Lancet study
0 notes
Text
Covaxin vaccine protects against 77.8% of coronavirus infections
Covaxin vaccine protects against 77.8% of coronavirus infections
A study by The Lancet medical journal reaffirmed that Covaxin inhibits the severity of Corona infection by 77.8 percent and against delta type Corona virus by up to 65.2 percent.
Vaccination in India has started on January 16.
Two vaccines are currently being administered in India, namely Covaxin and Covshield.
In India, Bharat Biotech, ICMR and Indian Virology Institute jointly discovered the…
View On WordPress
0 notes
Text
Covaxin 50% effective against symptomatic Covid cases: Lancet study | India News
Covaxin 50% effective against symptomatic Covid cases: Lancet study | India News
Two-dose of Covaxin, developed by Hyderabad-based Bharat Biotech, provided only 50 per cent protection against the Covid-19 infection during the second wave of the pandemic in India, according to the first real-world assessment published in The Lancet Infectious Diseases journal on Wednesday.
The study assessed 2,714 hospital workers from the All India Institute of Medical Sciences (AIIMS) in New…
View On WordPress
0 notes
Text
Covaxin Efficacy 77.8% In Lancet Study; 65.2% Against Delta In Early Data
Covaxin Efficacy 77.8% In Lancet Study; 65.2% Against Delta In Early Data
கோவாக்சின் பற்றிய லான்செட் ஆய்வு பாரத் பயோடெக் மற்றும் ஐசிஎம்ஆர் மூலம் நிதியளிக்கப்பட்டது.
புது தில்லி:
அரசாங்கத்தின் மருத்துவ ஆராய்ச்சி நிறுவனம் மற்றும் பாரத் பயோடெக் ஆகியவற்றால் உருவாக்கப்பட்ட கொரோனா வைரஸ் தடுப்பூசியான கோவாக்சின், தி லான்செட்டில் வெளியிடப்பட்ட நீண்டகாலமாக எதிர்பார்க்கப்பட்ட பகுப்பாய்வில், அறிகுறி COVID-19 க்கு எதிராக 77.8 சதவீத செயல்திறன் வீதத்தைக் கொண்டிருப்பது…
View On WordPress
0 notes
Last Seen Blogs
zuzumes
prev. hazelsinfinity
rattiazibidi-blog
Rattia Zibidi
tatt-probs
Tattoo Artist Problem
jaig-tano
Jaig Tano
pineappleciders
pineapple / cider